$44.72
0.52% day before yesterday
Nasdaq, Nov 28, 07:00 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Stock price

$44.72
+2.19 5.15% 1M
+16.23 56.97% 6M
+5.52 14.08% YTD
+1.57 3.64% 1Y
+8.25 22.62% 3Y
+32.83 276.11% 5Y
+35.48 383.98% 10Y
+34.22 325.90% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.23 0.52%
ISIN
CA98420N1050
Symbol
XENE
Industry

Key metrics

Basic
Market capitalization
$3.2b
Enterprise Value
$2.7b
Net debt
positive
Cash
$462.3m
Shares outstanding
77.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
424.1 | 414.1
EV/Sales
362.5 | 354.0
EV/FCF
negative
P/B
5.7
Financial Health
Equity Ratio
94.6%
Return on Equity
-31.0%
ROCE
-59.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $7.7m
EBITDA
$-338.2m | $-366.4m
EBIT
$-340.8m | $-367.6m
Net Income
$-306.3m | $-334.1m
Free Cash Flow
$-253.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-33.8% | -32.4%
EBIT
-33.4% | -31.6%
Net Income
-43.6% | -42.6%
Free Cash Flow
-53.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,509.5% | -4,770.5%
EBIT
-4,543.7%
Net
-4,084.5% | -4,349.8%
Free Cash Flow
-3,377.2%
More
EPS
$-3.9
FCF per Share
$-3.3
Short interest
8.7%
Employees
322
Rev per Employee
$0.0
Show more

Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Xenon Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

Buy
96%
Hold
4%

Financial data from Xenon Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
7.50 7.50
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 76 76
19% 19%
1,008%
- Research and Development Expense 273 273
42% 42%
3,636%
-338 -338
34% 34%
-4,510%
- Depreciation and Amortization 2.57 2.57
8% 8%
34%
EBIT (Operating Income) EBIT -341 -341
33% 33%
-4,544%
Net Profit -306 -306
44% 44%
-4,084%

In millions USD.

Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenon Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company's Na V 1.1 program in Dravet syndrome VANCOUVER, British Columbia and B...
Positive
Proactive Investors
4 days ago
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has secured its first foothold in Asia after National Taiwan University Hospital agreed to install one of the company's Xenon MRI research systems. The deal has been arranged through Philips, Polarean's long-standing strategic partner, and supported by Sumtage, the company's newly appointed distributor in Taiwan.
Neutral
GlobeNewsWire
23 days ago
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ...
More Xenon Pharmaceuticals Inc. News

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Head office Canada
CEO Ian Mortimer
Employees 322
Founded 1996
Website www.xenon-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today